相似文献
1
Research into rare diseases of childhood.
JAMA. 2014 May 7;311(17):1729-30. doi: 10.1001/jama.2013.285873.
2
Will the RACE for Children Act lead to new treatments for pediatric cancer?
Cancer. 2017 Jan 1;123(2):189. doi: 10.1002/cncr.30522.
3
Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
Eur Respir Rev. 2015 Sep;24(137):375-7. doi: 10.1183/16000617.0051-2015.
4
Orphan drugs: Indian perspective.
Indian J Pharmacol. 2017 Jul-Aug;49(4):267-269. doi: 10.4103/ijp.IJP_646_17.
5
The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.
J Popul Ther Clin Pharmacol. 2014;21(1):e47-55. Epub 2014 Feb 23.
6
Orphan drug development: an economically viable strategy for biopharma R&D.
Drug Discov Today. 2012 Jul;17(13-14):660-4. doi: 10.1016/j.drudis.2012.02.005. Epub 2012 Feb 17.
7
A new era of hope for the world's most neglected diseases.
PLoS Med. 2005 Sep;2(9):e323. doi: 10.1371/journal.pmed.0020323. Epub 2005 Sep 8.
8
Financing R&D for neglected diseases.
Nat Rev Drug Discov. 2009 Feb;8(2):91. doi: 10.1038/nrd2818.
9
Jumpstarting research into neglected diseases.
Cell. 2006 Nov 3;127(3):443-5. doi: 10.1016/j.cell.2006.10.022.
10
[Rare diseases: "a public health priorty". Interview by Catherine Holué].
Rev Prat. 2012 Jan;62(1):79-80.
引用本文的文献
1
Addressing the drug development challenge for rare pediatric diseases in Japan: a case study of isotretinoin.
Invest New Drugs. 2025 Jul 22. doi: 10.1007/s10637-025-01566-z.
2
Implementation of multi-omics in diagnosis of pediatric rare diseases.
Pediatr Res. 2025 Mar;97(4):1337-1344. doi: 10.1038/s41390-024-03728-w. Epub 2024 Nov 19.
3
Advance Care Planning for Children With Rare Diseases: A Pilot RCT.
Pediatrics. 2024 Jun 1;153(6). doi: 10.1542/peds.2023-064557.
4
How paediatrician researchers are advancing child health.
Nature. 2023 Oct;622(7983):S5-S9. doi: 10.1038/d41586-023-03234-9.
5
Being the Pillar for Children with Rare Diseases-A Systematic Review on Parental Quality of Life.
Int J Environ Res Public Health. 2021 May 8;18(9):4993. doi: 10.3390/ijerph18094993.
6
Advocacy Considerations for the Pediatric Pulmonologist in the Era of the COVID-19 Pandemic.
Ann Am Thorac Soc. 2021 Jun;18(6):942-945. doi: 10.1513/AnnalsATS.202008-1022PS.
7
Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).
Transl Sci Rare Dis. 2017 Dec 18;2(3-4):141-155. doi: 10.3233/TRD-170016.
8
The supportive care needs of parents with a child with a rare disease: results of an online survey.
BMC Fam Pract. 2016 Jul 21;17:88. doi: 10.1186/s12875-016-0488-x.
9
Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.
BMC Health Serv Res. 2016 Jul 11;16:241. doi: 10.1186/s12913-016-1477-4.
10
Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
CMAJ. 2015 Apr 7;187(6):422-425. doi: 10.1503/cmaj.140308. Epub 2015 Feb 23.
本文引用的文献
1
Expanded newborn screening for inborn errors of metabolism: overview and outcomes.
Adv Pediatr. 2012;59(1):209-45. doi: 10.1016/j.yapd.2012.04.013.
2
What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Pediatrics. 2012 Mar;129(3):516-21. doi: 10.1542/peds.2011-1798. Epub 2012 Feb 27.
3
Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies.
N Engl J Med. 1984 Jun 7;310(23):1500-5. doi: 10.1056/NEJM198406073102304.
4
The efficacy of dietary therapy for phenylketonuria.
Can Med Assoc J. 1971 Jun 19;104(12):1089-91.
Zotero 插件